U.S. Paper and Forestry Products Stock News

If you are wondering whether Aptiv's current share price lines up with its underlying value, you are not alone. This article is designed to help you frame that question clearly. Aptiv's stock last closed at US$79.72, with returns of 1.1% over 7 days, a 3.5% decline over 30 days, 1.6% year to date, a 25.6% gain over 1 year, and declines of 31.3% and 48.2% over 3 and 5 years respectively. Taken together, these figures give a mixed signal about growth potential and risk perception. Recent...

Tether has invested in and partnered with Gold.com, the parent company of NYSE:GOLD, to integrate tokenized gold into its platform. The collaboration will allow customers to use stablecoins to purchase physical gold through Gold.com. The move links a major stablecoin issuer with a large gold company, connecting blockchain based assets with physical bullion markets. For investors watching NYSE:GOLD, this partnership sits at the crossroads of traditional commodities and digital assets...

Structure Therapeutics (NasdaqGM:GPCR) has advanced its lead obesity candidate GSBR-1290 into phase 2 clinical trials as an oral treatment. The move comes as the company draws increased attention for targeting the obesity market with a pill-based approach rather than injectables. Analyst optimism and early discussion about potential takeovers have put fresh focus on the stock. Structure Therapeutics, trading under NasdaqGM:GPCR, is drawing fresh interest after pushing GSBR-1290 into phase...

RH recently reported third-quarter 2025 results showing year-over-year revenue growth and continued market share gains, alongside progress in expanding its gallery footprint and experiential concepts such as the RH Interior Design office and RH Ocean Grill. A separate development saw the departure of Chief Gallery & Customer Officer Stefan Duban in January 2026, with his responsibilities redistributed across existing leadership, highlighting how RH aims to support its growth initiatives...

MKS Inc. recently closed a private offering of €1.00 billion in 4.250% senior unsecured notes due 2034 and refinanced portions of its term loans and revolving credit facility, extending key maturities into the next decade and reducing interest margins on its dollar and euro borrowings. By replacing part of its secured term loan with unsecured notes and lowering interest costs, MKS has reshaped its capital structure in a way that may ease future financing pressure and improve financial...

If you are trying to figure out whether Molina Healthcare's share price reflects its true worth, the starting point is understanding how its current market price compares with a range of valuation checks. The stock last closed at US$176.84, with returns of a 4.4% decline over 7 days, 4.3% decline over 30 days, 0.9% decline year to date, 38.0% decline over 1 year, 41.3% decline over 3 years, and 18.2% decline over 5 years, which may have shifted how investors see its potential and its...

In early February 2026, Qualcomm reported record fiscal first‑quarter revenue of US$12.25 billion and net income of US$3.00 billion, but issued weaker second‑quarter guidance due to a global memory chip shortage constraining smartphone production. Alongside the earnings release, Qualcomm highlighted that strong demand for premium handsets and growing automotive and IoT contributions are being held back by supply bottlenecks rather than a lack of end‑market interest. We’ll now look at how...

Bio-Techne (TECH) has reported Q2 2026 revenue of US$295.9 million with basic EPS of US$0.24, alongside trailing twelve month revenue of about US$1.2 billion and EPS of US$0.52, setting up a mixed picture for growth and profitability. The company has seen quarterly revenue move between US$289.5 million and US$317.0 million over the past six reported periods, while basic EPS has ranged from a loss of US$0.11 to a recent run rate just above US$0.24. This matters for investors focused on how...

Why NCR Voyix (VYX) Is On Investors’ Radar Today NCR Voyix (VYX) is drawing fresh attention after a period of weak share performance, with the stock around $9.47 and total return figures over the past year and past 3 months reflecting double digit declines. With revenue of about $2.65b and a reported net loss of $62 million, investors are evaluating how this digital commerce business, focused on retailers and restaurants across multiple regions, is managing the balance between growth...

Tennant Company set the date for its 2026 annual meeting of shareholders. The company also announced the deadline for shareholders to nominate director candidates for the 2026 board election. The update outlines the timetable that will guide board nominations and voting for NYSE:TNC. Tennant, trading on the NYSE under ticker NYSE:TNC, recently closed at $80.84. The stock is up 5.5% over the past week, 5.0% over the past month, and 9.3% year to date, while showing a 4.1% decline over the...

PHINIA: recent returns and earnings context PHINIA (PHIN) has attracted attention after a recent period of positive share price performance, with the stock showing gains over the past week, month and past 3 months alongside reported revenue and net income figures. See our latest analysis for PHINIA. At a latest share price of US$71.08, PHINIA has seen a firm build up in momentum, with a 33.16% 3 month share price return and a 44.23% 1 year total shareholder return. These figures point to...

To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...

In early February 2026, JCapital Research released a critical report on Ondas Holdings, questioning its acquisition-driven business model, reliance on share issuance for funding, and aspects of management governance and financial sustainability. This scrutiny landed just as Ondas was expanding its defense-focused autonomous systems footprint through the planned acquisition of UK-based Rotron Aero and new government drone contracts. We’ll now explore how JCapital’s critique of Ondas’...

Coursera (NYSE:COUR) has entered into a merger agreement with Udemy, combining two major online learning platforms. The companies outlined expected annual cost synergies and product fit across their course catalogs and learner bases. Management also highlighted plans to use AI native products and data driven tools across the combined platform. Coursera is coming into this merger with a share price of $5.98 and a mixed recent track record, including a 22.3% decline over the past year and a...

What the SLAS2026 product launches mean for Revvity stock Revvity (RVTY) just used the SLAS2026 conference to roll out several new tools for high throughput drug discovery, including a high content screening system, a multimode plate reader, and an automated liquid handling workstation. For you as an investor, the focus is not the trade show itself, but what these launches say about how Revvity is trying to compete in automated, data heavy lab workflows that many pharma and biotech customers...

BioNTech (NasdaqGS:BNTX) has created a new Chief People Officer role. Kylie Jimenez has been appointed to the position, effective immediately. The move is tied to BioNTech’s goal of becoming a multi product oncology leader beyond its COVID 19 work. BioNTech, known widely for its COVID 19 vaccine partnership, is working to build a broader pipeline in oncology and other therapeutic areas. The new Chief People Officer role indicates that leadership views talent, organizational design, and...

If you are wondering whether ON Semiconductor's current share price reflects its true worth, this article will help you unpack what the numbers are saying about value. The stock last closed at US$63.10, with returns of 5.4% over 7 days, 2.0% over 30 days, 11.3% year to date, 23.1% over 1 year, a 24.7% decline over 3 years, and 52.9% over 5 years. Recent news coverage has focused on ON Semiconductor's role in key semiconductor end markets and how investors are weighing that against sector...

In recent days, Oklo has come under pressure as analyst reports and sector-wide weakness in uranium and nuclear-energy names raised questions about how higher nuclear fuel costs and easing geopolitical risk premiums could affect its advanced reactor business model. At the same time, the company still benefits from substantial U.S. government support and large-scale tech partnerships, creating an unusual mix of perceived opportunity and execution risk for a pre-revenue nuclear...

Proto Labs (PRLB) is back on investor radars after recent share price swings, prompting a closer look at how its digital manufacturing business, profitability, and recent returns fit into a broader portfolio. See our latest analysis for Proto Labs. Recent moves have been mixed, with a 1 day share price return of a 1.83% decline and a 90 day share price return of 7.12%, while the 1 year total shareholder return of 18.22% hints at improving momentum despite a weaker 5 year total shareholder...

Mettler-Toledo International Inc. recently reported its full-year 2025 results, with sales of US$4,026.40 million and net income of US$869.19 million, alongside higher basic and diluted earnings per share from continuing operations versus the prior year. The company also issued 2026 guidance calling for local currency sales increases in both the first quarter and full year, giving investors a clearer view of expected near-term business trends. Next, we’ll examine how Mettler-Toledo’s outlook...

Recently, Raytheon, an RTX business, entered into a series of long-term framework agreements with the U.S. Department of Defense to significantly expand production of key munitions including Tomahawk, AMRAAM, SM-3 and SM-6 missiles, backed by investments in facilities, technology and workforce over periods of up to seven years. The scale and duration of these missile production agreements highlight how deeply embedded RTX has become in U.S. defense modernization and high-volume weapons...

Johnson & Johnson (NYSE:JNJ) released new real world evidence on ERLEADA for metastatic castration sensitive prostate cancer. The study reports a significant survival benefit and reduced risk of death compared with darolutamide. The analysis follows FDA aligned methodological standards and provides head to head, real world comparative data. For a company like Johnson & Johnson, whose pharmaceutical arm is a core part of its business, real world data like this can be as important as headline...

Natera has recently advanced three major programs: launching the EDEN study for a new non-invasive prenatal preeclampsia risk test, submitting an FDA premarket approval application for its Signatera CDx assay in muscle-invasive bladder cancer, and completing enrollment in a key Prospera Heart trial aiming to reduce invasive biopsies in transplant care. Together, these moves highlight how Natera is trying to extend its cell-free DNA technology across prenatal health, oncology, and transplant...

Credo Technology Group Holding (NasdaqGS:CRDO) introduced its Blue Heron 224G AI scale up retimer for extended cable and backplane use in AI infrastructure. The product targets longer reach connections between GPUs and switch ICs while aiming to maintain high signal integrity. The launch focuses on AI data center deployments that require flexible rack and system layouts for hyperscale workloads. Credo Technology, through its networking and connectivity portfolio, is positioning this launch...